Shareholders back Immunic (NASDAQ: IMUX) 1-for-10 reverse stock split move
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Immunic, Inc. reported that stockholders approved a proposal authorizing its board to implement a reverse stock split of common stock at a ratio between 1-for-10 and 1-for-30. Of 130,464,825 shares outstanding on the record date, 70,622,667 shares, or about 54.1%, were represented at the special meeting.
Stockholders supported the proposal with 57,404,749 votes for, 12,594,555 against, and 623,363 abstentions. Following this approval, the board chose a 1-for-10 reverse stock split, expected to become effective at 12:01 a.m. Eastern Time on April 27, 2026, with the post-split shares trading on the Nasdaq Capital Market under the IMUX symbol.
Positive
- None.
Negative
- None.
Insights
Immunic shareholders approved, and the board set, a 1-for-10 reverse split to adjust the share count.
The company obtained stockholder authorization to conduct a reverse stock split within a 1-for-10 to 1-for-30 range and then selected a 1-for-10 ratio. This consolidates existing shares into fewer, higher-priced shares without changing overall ownership stakes.
The reverse split is expected to take effect at 12:01 a.m. Eastern Time on April 27, 2026, with the post-split stock continuing to trade on the Nasdaq Capital Market under the IMUX symbol. The filing notes typical forward-looking risks, including market conditions and the company’s cash needs, which could influence outcomes.
8-K Event Classification
2 items: 5.07, 8.01
2 items
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Shares outstanding on record date: 130,464,825 shares
Shares represented at meeting: 70,622,667 shares
Votes for proposal: 57,404,749 votes
+5 more
8 metrics
Shares outstanding on record date
130,464,825 shares
Common stock outstanding as of the record date for the special meeting
Shares represented at meeting
70,622,667 shares
Approximately 54.1% of outstanding shares present or by proxy at special meeting
Votes for proposal
57,404,749 votes
Votes in favor of reverse stock split authorization proposal
Votes against proposal
12,594,555 votes
Votes against reverse stock split authorization proposal
Abstentions
623,363 votes
Abstentions on reverse stock split authorization proposal
Reverse split ratio
1-for-10
Board-approved ratio for reverse stock split of common stock
Reverse split effective time
12:01 a.m. Eastern Time on April 27, 2026
Expected effectiveness of reverse stock split
New CUSIP
4525EP200
CUSIP identifier for Immunic common stock after reverse stock split
Key Terms
Special Meeting of Stockholders, Reverse Stock Split, Nasdaq Capital Market, forward-looking statements, +1 more
5 terms
Special Meeting of Stockholders financial
"On April 14, 2026, Immunic, Inc. ... held a Special Meeting of Stockholders"
A special meeting of stockholders is an unscheduled gathering called to let shareholders vote on specific, often urgent company decisions—like mergers, major asset sales, changes to the board, or amendments to governing rules. Think of it as an emergency town hall where owners cast ballots in person or by mail/online; outcomes can materially change a company’s strategy, control or value, so investors pay close attention and may need to vote or adjust holdings accordingly.
Reverse Stock Split financial
"to effect a reverse stock split ... at a ratio in the range of 1-for-10 to 1-for-30"
A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.
Nasdaq Capital Market financial
"New Common Stock will begin trading on the Nasdaq Capital Market on the post-split basis"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
forward-looking statements regulatory
"contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Proxy Statement regulatory
"described in more detail in the Company’s Definitive Proxy Statement filed ... on March 2, 2026"
A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.
FAQ
What did Immunic (IMUX) stockholders approve at the April 2026 special meeting?
Stockholders approved a proposal authorizing the board to implement a reverse stock split of Immunic’s common stock in a range of 1-for-10 to 1-for-30. This authorization lets the board choose the exact ratio and timing within that range, which they subsequently set at 1-for-10.
What reverse stock split ratio did Immunic (IMUX) ultimately choose?
The board approved a 1-for-10 reverse stock split of Immunic’s issued and outstanding common stock. Every ten existing shares will be combined into one new share, leaving total ownership percentages unchanged while reducing the number of shares outstanding and increasing the per-share price proportionally.
When will Immunic’s 1-for-10 reverse stock split become effective?
The 1-for-10 reverse stock split is expected to become effective at 12:01 a.m. Eastern Time on April 27, 2026. After this time, the company’s common stock will trade on a post-split basis, reflecting the new share count and split-adjusted price on the Nasdaq Capital Market.
Will Immunic’s ticker or exchange change after the reverse stock split?
Immunic’s common stock is expected to continue trading on the Nasdaq Capital Market under the existing ticker symbol IMUX after the reverse split. Only the share count and per-share price will adjust. The filing also notes a new CUSIP identifier, 4525EP200, for the post-split shares.
What risks does Immunic highlight regarding the reverse stock split timing?
Immunic notes that forward-looking statements about the reverse stock split’s timing may differ from actual results. It cites risks related to market conditions, the company’s cash needs, and broader business and financial uncertainties described in its Commission filings as potential factors affecting outcomes.